Loading...
XNYS
FMS
Market cap14bUSD
Mar 27, Last price  
24.55USD
1D
1.20%
1Q
6.88%
Jan 2017
-41.84%
Name

Fresenius Medical Care AG & Co KGaA

Chart & Performance

D1W1MN
P/E
12.32
P/S
0.34
EPS
1.83
Div Yield, %
2.80%
Shrs. gr., 5y
-0.62%
Rev. gr., 5y
2.04%
Revenues
19.34b
-0.61%
5,717,514,4996,439,636,1026,666,871,7637,623,256,1037,850,289,0469,063,019,1319,872,028,54310,434,945,23110,580,072,09813,019,603,52015,309,579,08017,030,495,24017,784,000,00016,547,000,00017,477,000,00017,859,000,00017,619,000,00019,398,000,00019,453,617,00019,335,909,000
Net income
538m
+7.80%
384,120,523406,687,076491,857,953587,319,812621,978,678735,746,932826,448,868897,393,757803,760,140859,366,200941,185,1401,181,894,1201,280,000,0001,982,000,0001,200,000,0001,164,377,000969,308,000673,405,000498,997,000537,913,000
CFO
2.39b
-9.23%
565,944,370687,853,712822,751,819730,119,339934,568,4401,028,693,1871,115,661,3001,541,817,0961,473,565,0841,530,411,9601,792,733,6002,034,797,6002,192,000,0002,062,000,0002,567,000,0004,233,000,0002,489,000,0002,167,000,0002,628,801,0002,386,144,000
Dividend
May 17, 20240.68831 USD/sh
Earnings
May 05, 2025

Profile

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
IPO date
Oct 02, 1996
Employees
124,295
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
19,335,909
-0.61%
19,453,617
0.29%
19,398,000
10.10%
Cost of revenue
17,905,569
14,760,582
14,317,000
Unusual Expense (Income)
NOPBT
1,430,340
4,693,035
5,081,000
NOPBT Margin
7.40%
24.12%
26.19%
Operating Taxes
316,056
300,557
325,000
Tax Rate
22.10%
6.40%
6.40%
NOPAT
1,114,284
4,392,478
4,756,000
Net income
537,913
7.80%
498,997
-25.90%
673,405
-30.53%
Dividends
(349,162)
(328,623)
(395,556)
Dividend yield
2.63%
2.69%
4.13%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,218,266
1,561,562
2,036,900
Long-term debt
13,901,343
14,634,796
15,854,435
Deferred revenue
34,018
9,474
Other long-term liabilities
1,634,456
2,502,833
1,716,379
Net debt
12,256,346
13,576,368
15,673,841
Cash flow
Cash from operating activities
2,386,144
2,628,801
2,167,000
CAPEX
(699,358)
(684,596)
(1,411,000)
Cash from investing activities
(84,939)
(544,227)
(734,725)
Cash from financing activities
(2,569,300)
(1,858,529)
(1,617,360)
FCF
1,935,349
431,592
4,250,819
Balance
Cash
1,446,576
1,539,778
1,443,770
Long term investments
1,416,687
1,080,212
773,724
Excess cash
1,896,468
1,647,309
1,247,594
Stockholders' equity
12,423,105
11,446,204
12,076,380
Invested Capital
26,519,427
27,732,471
28,871,964
ROIC
4.11%
15.52%
17.01%
ROCE
4.91%
15.97%
16.36%
EV
Common stock shares outstanding
293,413
293,413
293,246
Price
45.28
8.69%
41.66
27.48%
32.68
-49.66%
Market cap
13,285,761
8.69%
12,223,604
27.55%
9,583,293
-49.63%
EV
26,734,057
27,006,246
26,716,860
EBITDA
3,172,597
6,445,006
6,919,363
EV/EBITDA
8.43
4.19
3.86
Interest
407,044
424,640
360,000
Interest/NOPBT
28.46%
9.05%
7.09%